Background
==========

Osteoporosis is a complex bone disorder with a genetic background that leads to an increased susceptibility to bone fracture resulting in pain and morbidity \[[@b1-medscimonit-23-5113]\]. The prevalence of osteoporosis increases with age and, in their lifetime, affects up to 30% of women and 12% of men, worldwide \[[@b1-medscimonit-23-5113]\]. Recently, several treatments have become available for osteoporosis, including estrogen therapy, calcium supplementation, and other hormonal treatments \[[@b2-medscimonit-23-5113], [@b3-medscimonit-23-5113]\].

Chinese herbal medicines have been evaluated for their effects on bone metabolism in preclinical and clinical studies \[[@b4-medscimonit-23-5113]\]. *Curculigo orchioides* (CO) has been widely used as a traditional Chinese and Indian herbal medicine for osteoporosis \[[@b5-medscimonit-23-5113]\]. Our previous studies have shown that some components of CO have anti-osteoporotic activity \[[@b6-medscimonit-23-5113]\]. For example, curculigoside B has been shown to inhibit bone resorption and curculigoside can reverse H~2~O~2~-induced stimulation of extracellular signal-regulated kinase 1/2, and nuclear factor-κB signaling and inhibit p38 mitogen-activated protein kinase activation \[[@b6-medscimonit-23-5113]\]. Although some mechanisms for the therapeutic action of CO have been previously reported, there are no existing studies that demonstrate the complex mechanisms of action of CO.

CO has been reported to contain saponins, phenols, and phenolic glycosides, triterpenes, triterpenoid glycosides and other compounds \[[@b6-medscimonit-23-5113]\]. In our previous reports, an ultra-high performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry method (UPLC-TOF-MS) was used to identify 45 chemical constituents in CO \[[@b6-medscimonit-23-5113]\]. However, analysis of several active compounds in CO could not identify the pharmacological targets of CO, possibly because multiple components could hit multiple targets and exert synergistic therapeutic efficacies. Therefore, a comprehensive method that reflects the variation of most components in the crude drug, and more importantly, identifies the targets of the drug, is required.

With the emergence of systems biology, network pharmacology has become a promising paradigm for future drug development \[[@b7-medscimonit-23-5113]\]. Molecular networks of complex components and multilevel target-based protein and gene interactions can now be constructed for predicting functions of compounds and promoting discovery of active compounds \[[@b8-medscimonit-23-5113]\]. Thus, the application of network pharmacology could provide new opportunities to understand the interactions between active compounds and relevant targets, which in turn may highlight the mechanisms of action \[[@b9-medscimonit-23-5113]\]. The aim of this study was to identify the absorbable components, potential targets, and associated treatment pathways of CO using a network pharmacology approach.

Material and Methods
====================

Construction of chemical structures
-----------------------------------

All chemicals from *Curculigo orchioides* (CO) were collected from the following: ultra-performance liquid chromatography coupled to time-of-flight mass spectrometry (UPLC-TOF-MS) analysis \[[@b6-medscimonit-23-5113]\]; Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) (*<http://lsp.nwsuaf.edu.cn/tcmsp.php>*); and literature review. A total of 77 chemicals were identified in CO. And the chemical structures were obtained from the Chemical Book (*<http://www.chemicalbook.com>*), and presented using ChemDraw software.

Calculation and prediction of absorbable chemical components
------------------------------------------------------------

ChemDraw software was used to obtain the format of the chemical components. Then, we import the SMILES format into the Molinspiration SMILES website (*<http://www.molinspiration.com/>*) to calculate the predictive parameters for drug absorption. According to the five principles of drug absorption, a compound could be identified as an absorbable drug if: the hydrogen bond donor (the number of hydrogen atoms attached to the O and N, nOHNH) ≤5; hydrogen bond acceptor (the number of O and N, nON) ≤10; fat water partition coefficient (miLogP) ≤5; and relative molecular mass (MW) ≤500.

Prediction and screening of targets
-----------------------------------

Using the ChemBio3D Ultra 12.0 informatics system, we transformed the structure of the absorbed components into the MOL2 structure format. To predict possible targets for CO, we imported the components into the public network server of the database of the efficacy group PharmaMapper server website (*<http://59.7896.61/pharmmapper/>*) to perform reverse docking. The top ten targets of each compound were selected for subsequent study.

The Therapeutic Target Database \[[@b10-medscimonit-23-5113]\] and Search Tool for the Retrieval of Interacting Genes (STRING) database (version 10.0) (*<http://string-db.org>*) \[[@b11-medscimonit-23-5113]\] were used to predict the potential interactions among the targets.

Prediction and screening of pathways and diseases
-------------------------------------------------

The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed using the Comparative Toxicogenomics Database (CTD) (*<http://ctdbase.org/>*) to study the functions and processes that might be altered by the identified targets \[[@b12-medscimonit-23-5113]\]. The cut-off value for the screening of significant functions and pathways was P\<0.01.

The potential targets were connected with the related diseases, which were obtained from the PharmGKB database \[[@b13-medscimonit-23-5113]\].

Construction of the network
---------------------------

According to the top 40 pathways with their corresponding targets, the diseases, and the components, we constructed a multiple components-multiple target-multiple pathways-multiple disease network using Cytoscape (version 3.4.2; *<http://www.cytoscape.org/>*). \[[@b14-medscimonit-23-5113]\] Then, according to the three main targets, we drew a main compounds-main target-main pathway diagram.

Results
=======

Absorption parameters of chemical components
--------------------------------------------

The oral route is a convenient and usual way to deliver drugs to the systemic circulation for patients \[[@b15-medscimonit-23-5113]\]. In this study, a total of 77 components of *Curculigo orchioides* (CO) were identified. For some natural compounds with poor aqueous solubility, they would be expected to exhibit low efficiency after oral intake, and thereby provide few beneficial therapeutic effects in patients. Therefore, a computer prediction approach was used to calculate the absorption parameters of the identified components.

[Table 1](#t1-medscimonit-23-5113){ref-type="table"} shows the specific absorption parameters of all of the components. The data indicated that there was a total of 32 chemical components that met the five principles of drug absorption.

Target prediction and validation
--------------------------------

By importing 32 chemical components that were predicted to be absorbable into the PharmMapper database for directional docking, a total of 83 targets were obtained. These targets were imported into the Comparative Toxicogenomics Database (CTD) database and 58 pathways were obtained that were regulated by CO, with significant differences (*P*\<0.01). The top 40 pathways are listed in [Table 2](#t2-medscimonit-23-5113){ref-type="table"}.

Pharmacology network of CO
--------------------------

Using the Cytoscape merge tool, we constructed a pharmacology network for CO, which presented the relationships of the top 40 pathways, targets, diseases, and chemical components. [Figure 1](#f1-medscimonit-23-5113){ref-type="fig"} shows the preliminary understanding of the mechanism of CO through this network.

Data analysis showed that the genes for estrogen receptor alpha (*ESR1*) and beta (*ESR2*), and the gene for 11 beta-hydroxysteroid dehydrogenase type 1, or cortisone reductase (*HSD11B1*) were the main targets of CO. [Figure 2](#f2-medscimonit-23-5113){ref-type="fig"} shows the main targets with their corresponding compounds and pathways. [Figure 2C](#f2-medscimonit-23-5113){ref-type="fig"} shows a molecular docking simulation and that the ten components had strong binding efficiencies with the three main targets of CO.

Discussion
==========

Osteoporosis is characterized by low bone mineral density, leading to increased bone fragility risk \[[@b16-medscimonit-23-5113]\]. *Curculigo orchioides* (CO) exerts therapeutic effects on osteoporosis. Although this complex Chinese herbal medicine is used for the treatment of various diseases, some questions remain regarding its mechanism of action. In this study, we constructed multilayer networks to predict drug targets in a holistic manner, using a pharmacological drug discovery approach that included identification of the gene-targets and the use of the multiple components-multiple targets-multiple pathways-multiple disease approach. As this study has shown, the availability of large phenotypic and molecular networks may provide an opportunity to study the association between diseases and proteomics datasets.

In this study, data analysis showed that the genes for estrogen receptor alpha (*ESR1*) and beta (*ESR2*), and the gene for 11 beta-hydroxysteroid dehydrogenase type 1, or cortisone reductase (*HSD11B1*) were the main targets of CO. This study also predicted the absorbable chemical components of CO, previously reported to include saponins, phenolic compounds and glycosides \[[@b17-medscimonit-23-5113]\]. Our previous studies have shown that glucosides from CO could significantly increase t bone mineral density, improve the microarchitecture of bone tissue, inhibit the increase of malondialdehyde in serum, and reduce the excretion of urinary calcium in ovariectomized rats \[[@b17-medscimonit-23-5113]\]. In addition, although the six glycosides, curculigosaponin G, curculigoside B, curculigosaponin E, curculigosaponin J, curculigosaponin L, and curculigoside C, could not be absorbed directly, they could be divided into aglycones, which can be absorbed into the body.

In this study, the validated potential targets for CO were related with seven diseases, including osteoporosis, diabetes, stroke, pancreatitis, myocardial infarction, prostate and breast cancer \[[@b18-medscimonit-23-5113]\]. Osteoporosis has a relationship with these other six diseases. For example, osteoporosis is one of the major complications of diabetes. Bone marrow mesenchymal stem cells give rise to both osteoblasts and adipocytes, adipokines control energy homeostasis, but also have actions on the skeleton \[[@b18-medscimonit-23-5113]\]. Patients with chronic pancreatitis may be at an increased risk of low bone density because of malabsorption of vitamin D and calcium, poor diet, pain, alcoholism, and smoking \[[@b19-medscimonit-23-5113]\]. Prostate and breast cancer patients experience osteoporosis resulting from accelerated loss of bone mineral density caused by their treatment \[[@b20-medscimonit-23-5113]\]. This suggests that CO might be effective not only in the treatment of primary osteoporosis, but also in the prevention of secondary osteoporosis \[[@b21-medscimonit-23-5113]\].

Based on illustration of the main targets with their corresponding compounds, we found three major gene targets for CO: *ESR1*, *ESR2*, and *HSD11B1*. *ESR1* and *ESR2* genes encode estrogen receptors, involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis \[[@b22-medscimonit-23-5113]\]. *ESR1* is expressed in osteoblasts and osteoclasts, and is associated with postmenopausal osteoporosis of the spine in women \[[@b22-medscimonit-23-5113],[@b23-medscimonit-23-5113]\]. This gene could be employed as a selection method to identify individuals at increased risk of osteoporosis \[[@b23-medscimonit-23-5113]\]. In a previous large population-based cohort study, variants in the *ESR2* gene were associated with an increased risk of vertebral fracture in postmenopausal women \[[@b24-medscimonit-23-5113]\]. The 11 beta-hydroxysteroid dehydrogenase type 1 gene (*HSD11B1*) is a primary regulator catalyzing the reduction of inactive cortisone to active cortisol \[[@b25-medscimonit-23-5113]\]. Polymorphisms of the *HSD11B1* gene have been previously shown to affect the function of the 11β-HSD1 enzyme and *HSD11B1* polymorphisms have been shown to be predictive of bone mineral density and the risk of bone fracture in postmenopausal women without a clinically apparent hypercortisolemia \[[@b25-medscimonit-23-5113]\].

In this study, endocrine and other factors regulated calcium reabsorption, steroid hormone biosynthesis, and metabolic pathways were related with the main targets and ten corresponding compounds. Estrogen is an important steroid hormone that is involved in the process of osteoblast differentiation regulated by bone morphogenetic proteins (BMPs) and tumor necrosis factor (TNF)-α \[[@b26-medscimonit-23-5113]\]. BMPs could increase the sensitivity of estrogen receptors, whereas estrogen differentially regulates BMP-Smad and TNF-α signaling \[[@b26-medscimonit-23-5113]\].

Ethanol extracts of CO have been shown to possess estrogenic activity. A molecular docking simulation was performed and the results ([Figure 2C](#f2-medscimonit-23-5113){ref-type="fig"}) showed that the ten components had strong binding efficiencies with the three main targets of CO. These compounds were considered as the main components that mediated the estrogen-like efficacy of CO.

This is the first report to show the mechanism of CO using a network pharmacology approach, and we successfully predicted the main targets and pathways for CO, providing the basis for further research. This approach would also benefit other studies of Chinese herbal medicines and complex drugs. The findings of this study indicate that CO, a widely used herbal medicine for the treatment of osteoporosis, has its therapeutic effects through multiple targets and multiple pathways. However, it must be stressed that computational models can only provide network data-driven indications for complex therapeutic compounds and the findings of this study should be verified by controlled clinical studies and real-world evidence.

Conclusions
===========

This study has demonstrated a novel approach for the investigation of the mechanism of action of the Chinese herbal medicine, *Curculigo orchioides* (CO), by combining absorption property screening, targes prediction, and network pharmacology. The network pharmacology approach used in our study has attempted to explain the mechanisms for the effects of CO in the prevention and treatment of osteoporosis, and provides an alternative approach to the investigation of the effects of this complex compound.
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###### 

Absorption parameters of the components of *Curculigo orchioides* (CO).

  No.   Molecule Name                                                                                                                     MW         miLogP   nON   nOHNH   Results
  ----- --------------------------------------------------------------------------------------------------------------------------------- ---------- -------- ----- ------- ---------
  1     Palmitic acid                                                                                                                     256.48     6.37     1     2       ×
  2     Neral                                                                                                                             152.26     3.19     0     1       ✓
  3     Sitogluside                                                                                                                       576.95     6.34     4     6       ×
  4     Beta-sitosterol                                                                                                                   414.79     8.08     1     1       ×
  5     (+)-Syringaresinol                                                                                                                418.48     2.1      2     8       ✓
  6     Stigmasterol                                                                                                                      412.77     7.64     1     1       ×
  7     Oleic acid                                                                                                                        282.52     6.84     1     2       ×
  8     Hyacinthin                                                                                                                        120.16     1.52     0     1       ✓
  9     3-Methoxyanisole                                                                                                                  138.18     1.8      0     2       ✓
  10    Stearic acid                                                                                                                      284.54     7.28     1     2       ×
  11    Methyl palmitate                                                                                                                  270.51     6.62     0     2       ×
  12    Ethylpalmitate                                                                                                                    284.54     6.97     0     2       ×
  13    Myristic acid                                                                                                                     228.42     5.46     1     2       ×
  14    Pentadecylic acid                                                                                                                 242.45     5.91     1     2       ×
  15    Daturic acid                                                                                                                      270.51     6.82     1     2       ×
  16    ZINC03982454                                                                                                                      414.79     8.08     1     1       ×
  17    Toluene                                                                                                                           92.15      2.32     0     0       ✓
  18    Tetramethylpyrazine                                                                                                               136.22     0.66     0     2       ✓
  19    3,4,5-Trimethoxytoluene                                                                                                           182.24     2.27     0     3       ✓
  20    Cycloartenol                                                                                                                      426.8      7.55     1     1       ×
  21    Caffeine                                                                                                                          194.22     −0.1     0     5       ✓
  22    (E)-6-Methyl-3,5-heptadien-2-one                                                                                                  152.26     2.89     0     1       ✓
  23    3,2′,4′,6′-Tetrahydroxy-4,3′-dimethoxy chalcone                                                                                   332.33     2.6      4     7       ✓
  24    3,3′,5,5′-Tetramethoxy-7,9′7′,9-diepoxy-lignan-4,4′-di-O-β-D-glucopyranoside                                                      742.8      −1.71    8     18      ×
  25    Methyl 5-acetyl-1,2,3,5,6-oxatetrazinane-3-carboxylate                                                                            190.19     −1.6     2     8       ✓
  26    4-Methyl heptadecanoic acid                                                                                                       284.54     7.08     1     2       ×
  27    4-Acetyl-2-methyoxy-5-methyltriacontane                                                                                           509.02     12.56    0     2       ×
  28    5-Methylfurfural                                                                                                                  110.12     1.13     0     2       ✓
  29    Curculigin C                                                                                                                      535.79     0.89     6     11      ×
  30    2,4,6-Trichloro-3-methoxy-5-methylphenol                                                                                          241.5      4.03     1     2       ✓
  31    Curculigosaponin G                                                                                                                783.12     1.58     8     13      ×
  32    Curculigosaponin G_qt                                                                                                             474.8      4.18     3     4       ✓
  33    Curculigoside B                                                                                                                   452.45     0.55     6     11      ×
  34    Curculigoside B_qt                                                                                                                290.29     2.45     3     6       ✓
  35    Curculigoside                                                                                                                     466.48     0.8      5     11      ×
  36    Curcumadiol                                                                                                                       238.41     2.56     2     2       ✓
  37    Curculigoside_qt                                                                                                                  304.32     2.7      2     6       ✓
  38    Tetramethylsuccinamide                                                                                                            172.26     −0.79    0     4       ✓
  39    N-acetyl-N-hydroxy-2-carbamic acid methylester                                                                                    133.12     −0.56    1     5       ✓
  40    1-Bromo-2-methoxynaphthalene                                                                                                      237.1      3.47     0     1       ✓
  41    Orcinol glucoside                                                                                                                 286.31     −0.12    5     7       ✓
  42    Orcin                                                                                                                             124.15     1.78     2     2       ✓
  43    2,3,4,7-Tetramethoxyxanthone                                                                                                      316.33     2.9      0     6       ✓
  44    Lycorine                                                                                                                          287.34     0.71     2     5       ✓
  45    Yuccagenin                                                                                                                        430.69     3.67     2     4       ✓
  46    Corchioside A                                                                                                                     418.44     −1.36    7     11      ×
  47    Curculigine A                                                                                                                     531.38     −0.29    7     12      ×
  48    2,4-Dichloro-5-methoxy-3-methylphenol                                                                                             207.06     3.36     1     2       ✓
  49    Curculigine B                                                                                                                     501.35     0.05     6     11      ×
  50    Curculigosaponin A                                                                                                                636.96     2.43     6     9       ×
  51    Curculigosaponin E_qt                                                                                                             474.8      4.18     3     4       ✓
  52    Curculigosaponin B                                                                                                                606.93     2.94     5     8       ✓
  53    Curculigosaponin C                                                                                                                769.09     1.2      8     13      ×
  54    Curculigosaponin D                                                                                                                799.12     0.69     9     14      ×
  55    Curculigosaponin E                                                                                                                931.25     −0.55    11    18      ×
  56    Curculigosaponin F                                                                                                                961.28     −1.06    12    19      ×
  57    Curculigosaponin J_qt                                                                                                             474.8      4.18     3     4       ✓
  58    Curculigosaponin G                                                                                                                783.12     1.58     8     13      ×
  59    Curculigosaponin H                                                                                                                915.25     0.34     10    17      ×
  60    2,3,5-Trimethylphenathrene                                                                                                        220.33     5.11     0     0       ×
  61    Cynanuriculoside A_qt                                                                                                             923.27     2.9      4     16      ×
  62    Curculigosaponin I                                                                                                                945.28     −0.17    11    18      ×
  63    Curculigosaponin J                                                                                                                1,077.41   −1.41    13    22      ×
  64    Curculigosaponin K                                                                                                                963.3      −0.88    13    19      ×
  65    Curculigosaponin L_qt                                                                                                             476.82     4.36     4     4       ✓
  66    Curculigosaponin L                                                                                                                785.14     1.76     9     13      ×
  67    Curculigosaponin M                                                                                                                1,077.41   −1.19    14    22      ×
  68    Curculigosaponin M_qt                                                                                                             458.8      5.28     3     3       ×
  69    Curculigenin A                                                                                                                    474.8      4.18     3     4       ✓
  70    Curculigenin B                                                                                                                    476.82     4.36     4     4       ✓
  71    Curculigenin C                                                                                                                    458.8      5.28     3     3       ×
  72    \[5-Hydroxy-2-\[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl\]oxyphenyl\]methyl 3-hydroxy-2,6-dimethoxybenzoate   482.48     0.53     6     12      ×
  73    Curculigoside C_qt                                                                                                                320.32     2.43     3     7       ✓
  74    2,6-Dimethoxybenzoic acid                                                                                                         182.19     1.4      1     4       ✓
  75    Curculigol                                                                                                                        456.83     6.59     2     2       ×
  76    2-Propyl-1-heptanol                                                                                                               158.32     3.57     1     1       ✓
  77    DBQ                                                                                                                               220.34     3.13     0     2       ✓

###### 

Top 40 KEGG pathways regulated by *Curculigo orchioides* (CO) (*P*\<0.01).

  No   Pathway                                                     Pathway ID    P-value    q-value    Annotated genes quantity
  ---- ----------------------------------------------------------- ------------- ---------- ---------- --------------------------
  1    Metabolic pathways                                          KEGG: 01100   3.99E-10   5.98E-08   15
  2    Prostate cancer                                             KEGG: 05215   7.06E-09   1.06E-06   6
  3    Progesterone-mediated oocyte maturation                     KEGG: 04914   3.22E-07   4.83E-05   5
  4    Bile secretion                                              KEGG: 04976   1.06E-07   1.59E-05   5
  5    Galactose metabolism                                        KEGG: 00052   2.66E-07   3.99E-05   4
  6    Purine metabolism                                           KEGG: 00230   1.63E-04   0.02446    4
  7    Natural killer cell mediated cytotoxicity                   KEGG: 04650   8.12E-05   0.01217    4
  8    T cell receptor signaling pathway                           KEGG: 04660   2.69E-05   0.00403    4
  9    Insulin signaling pathway                                   KEGG: 04910   8.55E-05   0.01283    4
  10   Pancreatic secretion                                        KEGG: 04972   2.41E-05   0.00362    4
  11   Hepatitis C                                                 KEGG: 05160   6.71E-05   0.01006    4
  12   Steroid hormone biosynthesis                                KEGG: 00140   1.14E-04   0.01716    3
  13   Amino sugar and nucleotide sugar metabolism                 KEGG: 00520   7.89E-05   0.01184    3
  14   MAPK signaling pathway                                      KEGG: 04010   0.00997    1          3
  15   ErbB signaling pathway                                      KEGG: 04012   4.05E-04   0.06079    3
  16   Cell cycle                                                  KEGG: 04110   0.00104    0.15528    3
  17   Oocyte meiosis                                              KEGG: 04114   8.17E-04   0.1225     3
  18   p53 signaling pathway                                       KEGG: 04115   1.73E-04   0.02602    3
  19   Wnt signaling pathway                                       KEGG: 04310   0.00211    0.3172     3
  20   Focal adhesion                                              KEGG: 04510   0.00437    0.65545    3
  21   Regulation of actin cytoskeleton                            KEGG: 04810   0.00497    0.7454     3
  22   Endocrine and other factor-regulated calcium reabsorption   KEGG: 04961   6.63E-05   0.00994    3
  23   Gastric acid secretion                                      KEGG: 04971   2.22E-04   0.03331    3
  24   Alzheimer's disease                                         KEGG: 05010   0.0025     0.37548    3
  25   Tuberculosis                                                KEGG: 05152   0.00302    0.45366    3
  26   Colorectal cancer                                           KEGG: 05210   1.39E-04   0.0208     3
  27   Acute myeloid leukemia                                      KEGG: 05221   9.82E-05   0.01472    3
  28   Small cell lung cancer                                      KEGG: 05222   3.44E-04   0.0516     3
  29   Non-small cell lung cancer                                  KEGG: 05223   8.35E-05   0.01252    3
  30   Primary immunodeficiency                                    KEGG: 05340   2.67E-05   0.004      3
  31   Glutathione metabolism                                      KEGG: 00480   0.00299    0.44822    2
  32   Folate biosynthesis                                         KEGG: 00790   2.46E-04   0.03683    2
  33   Metabolism of xenobiotics by cytochrome P450                KEGG: 00980   0.00565    0.84694    2
  34   Drug metabolism -- cytochrome P450                          KEGG: 00982   0.00595    0.89321    2
  35   PPAR signaling pathway                                      KEGG: 03320   0.00595    0.89321    2
  36   Apoptosis                                                   KEGG: 04210   0.00869    1          2
  37   Hedgehog signaling pathway                                  KEGG: 04340   0.00396    0.59355    2
  38   VEGF signaling pathway                                      KEGG: 04370   0.00693    1          2
  39   NOD-like receptor signaling pathway                         KEGG: 04621   0.00409    0.61306    2
  40   Long-term potentiation                                      KEGG: 04720   0.00549    0.82423    2
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